Johnson & Johnson (JNJ) reported Q1 FY2025 earnings of $2.77 per share (versus $2.71 per share in Q1 FY2024), beating analysts’ consensus estimate of $2.58 per share.
The company’s quarterly revenues amounted to $21.893 bln (+2.4% y/y), beating analysts’ consensus estimate of $21.559 bln.
The company also issued guidance for FY2025, seeing EPS of $10.50-10.70 versus analysts’ consensus estimate of $10.46 and revenues of $91.0-91.8 bln versus analysts’ consensus estimate of $90.27 bln.
JNJ rose to $155.00 (+0.41%) in pre-market trading.
